And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, not surprisingly, is exceedingly modest. We plan to catch up on our reading, promenade with the official mascot, and check in on the Pharmalot ancestors. And what about you? This is a fine time to enjoy the great outdoors, tidy up around your castle, or touch base with those who may feel isolated. Well, whatever you do, have a grand time. But remember, be safe and wear a mask. Enjoy, and see you soon. …

BioNTech, which has partnered with Pfizer (PFE) to develop a Covid-19 vaccine, is confident it will be ready to seek regulatory approval by the end of the year, and several hundred million doses could be produced even before approval, and over 1 billion by the end of 2021, The Wall Street Journal writes. The vaccine BioNTech is developing uses experimental technology known as messenger RNA, or mRNA. Pending approval by authorities, BioNTech expects to begin the final stage of the testing process, known as Phase 3 trials, at the end of July.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy